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Chronic inflammation is considered a causal risk factor predisposing to insulin resistance. However, evidence is accumulating
that inflammation confined to the liver may not be causal to metabolic dysfunction. To investigate this, we assessed if hepatic
inflammation explains the predisposition towards insulin resistance in low-density lipoprotein receptor knock-out (Ldlr−/−) mice.
For this, wild type (WT) and Ldlr−/− mice were fed a chow diet, a high fat (HF) diet, or a high fat, high cholesterol (HFC) diet
for 2 weeks. Plasma lipid levels were elevated in chow-fed Ldlr−/− mice compared to WT mice. Although short-term HF or HFC
feeding did not result in body weight gain and adipose tissue inflammation, dyslipidemia was worsened in Ldlr−/− mice compared
to WT mice. In addition, dyslipidemic HF-fed Ldlr−/− mice had a higher hepatic glucose production rate than HF-fed WT mice,
while peripheral insulin resistance was unaffected. This suggests that HF-fed Ldlr−/− mice suffered from hepatic insulin resistance.
While HFC-fed Ldlr−/− mice displayed the anticipated increased hepatic inflammation, this did neither exacerbate systemic nor
hepatic insulin resistance. Therefore, our results show that hepatic insulin resistance is unrelated to cholesterol-induced hepatic
inflammation in Ldlr−/− mice, indicating that hepatic inflammation may not contribute to metabolic dysfunction per se.
1. Introduction
Obesity is linked to many deleterious health consequences,
including insulin resistance, type 2 diabetes (T2D) and
the metabolic syndrome, a group of metabolic risk factors
predisposing to T2D, and cardiovascular disease. Low-grade,
chronic inflammation is considered as one of themost impor-
tantmechanisms explaining the etiology of insulin resistance,
T2D, and the metabolic syndrome [1]. However, evidence is
accumulating that inflammation when confined to the liver
may not be causal to metabolic dysfunction in obesity (for
review see [2]). For instance, we recently demonstrated that
hepatic inflammation does not contribute to insulin resis-
tance in TNFR1-non-sheddable mice expressing a mutated
TNFR1 ectodomain incapable of shedding and dampening
the hepatic inflammatory response [3]. Furthermore, we
showed that cholesterol-induced hepatic inflammation does
not advance the development of systemic insulin resistance
in male Ldlr−/− mice [4]. Being consistent with the outcome
of these gain-of-function studies, others have shown that
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reduced hepatic inflammation not necessarily corresponds to
enhanced insulin sensitivity in mice [5, 6], further indicating
that factors other than hepatic inflammationmay be causal in
triggering insulin resistance.
Dyslipidemia, provoked by elevated plasma low-density
lipoprotein (LDL) cholesterol and/or very low-density lipo-
protein (VLDL) triglycerides levels and decreased high-
density lipoprotein (HDL) cholesterol levels, may be such
a causal factor in the development of insulin resistance
[7]. Indeed, several studies have shown that dyslipidemia
is an independent predictor of insulin resistance and T2D
[8, 9]. Furthermore, lipid-lowering drugs have been shown
to exhibit a positive effect on insulin sensitivity [10]. Nev-
ertheless, dyslipidemia may also occur as a result of insulin
resistance since hepatic lipogenesis, in contrast to gluconeo-
genesis, remains sensitive to insulin [11]. This leads to an
increased production of plasma lipids due to overstimulation
of insulin receptor pathways caused by hyperinsulinemia
[11]. Hampered by the coexisting nature of dyslipidemia and
obesity, its exact role in the etiology of insulin resistance
therefore remains ill defined.
To further elaborate on these studies, we assessed the
extent to which hepatic inflammation may explain the
reported predisposition towards insulin resistance in dyslipi-
demic Ldlr−/−mice [12]. Furthermore, the rapid development
of dyslipidemia [13, 14] and hepatic inflammation [14, 15]
in these mice allows us to investigate their effect on insulin
resistance before alterations in body weight occur. We opted
to use female mice only as they confer a natural resistance
against diet-induced obesity. This is of particular importance
as adiposity drives the metabolic phenotype in most studies
[2] and differences in insulin resistance have been shown to
disappear after matching the mice for body weight [16]. Our
data show that hepatic inflammation is not a causal factor
in the development of hepatic insulin resistance in Ldlr−/−
mice. Thus, in line with the studies mentioned above, but
contrastingwith the current dogma, our data donot support a
role for hepatic inflammation in triggering insulin resistance.
2. Research Design and Methods
2.1. Animals and Diets. Age-matched (12–16 weeks) female
Ldlr−/− mice on a C57BL/6J background [13] and wild
type (WT) C57BL/6J mice were used for all experiments.
Breeding pairs of Ldlr−/− mice were obtained from the
Jackson Laboratory (Bar Harbor, ME, USA) and Ldlr−/−mice
were bred in house. WT mice were purchased from Charles
River (France). Mice were placed on a standard rodent chow
diet, a high fat (HF) diet (containing 21% fat from milk
butter and 0.02% cholesterol; Scientific Animal Food and
Engineering, Villemoisson-sur-Orge, France), or a high fat,
high cholesterol (HFC) diet (containing 21% fat from milk
butter and 0.2% cholesterol; Scientific Animal Food and
Engineering, Villemoisson-sur-Orge, France) for a period
of 2 weeks with ad libitum access to food and water. Mice
were housed individually and kept on a 12-hour light/12-
hour dark cycle. Animals were anesthetized by isoflurane
during all surgical operations and discomfort was minimized
as much as possible. All animal experiments were approved
by the ethics committee of the University of Groningen,
which adheres to the principles and guidelines established by
the European Convention for the Protection of Laboratory
Animals.
2.2. Oral Glucose Tolerance Test and Intraperitoneal Insulin
Tolerance Test. Mice were fasted for 6 hours before perform-
ing an oral glucose tolerance test (OGTT) or an insulin
tolerance test (ITT). For the OGTT, a glucose bolus of 2 g/kg
body weight of 20% glucose solution was given by gavage. For
the ITT, an insulin dose of 0.3U/kg body weight was injected
intraperitoneally. Glucose levels were measured with a One
Touch Ultra glucose meter before the test and at 15, 30, 60,
90, and 120 minutes after gavage or injection. In addition,
fasted insulin levels were measured with an ultrasensitive
insulin ELISA kit (Alpco Diagnostics, Salem, NH). The
homeostasis model assessment of insulin resistance (HOMA-
IR) was calculated from fasted insulin and glucose levels
(fasted insulin (𝜇U/mL) × fasted glucose (mmol/liter)/22.5).
2.3. Hyperinsulinemic-Euglycemic Clamp. A hyperinsuline-
mic-euglycemic clamp (HIEC) was performed in conscious
mice as described previously [17], with a modified protocol.
In brief, mice were cannulated in the right vena jugularis to
allow infusion of fluids for an HIEC. They were allowed to
recover for 5–7 days before the HIEC was started. Before
the HIEC, mice were fasted overnight for 9 hours and
placed in experimental cages. Mice were infused at a rate of
0.10mL/h for 4 hours with a solution containing 1% bovine
serum albumin (Sigma Aldrich, Zwijndrecht, Netherlands),
30% glucose (3% [U-13C] glucose; 27% glucose), 110mU/mL
insulin (Actrapid, Novo Nordisk, Bagsvaerd, Denmark), and
40 𝜇g/mL somatostatin (Eumedica NV, Brussels, Belgium).
To maintain euglycemia, a 30% glucose solution was infused
(3% [U-13C] glucose; 27% glucose) via a second line and
pump speeds were adjusted to the needs of the animal. Every
15min, a blood sample was taken from the tail vein to deter-
mine plasma glucose levels, and every 30 minutes, a blood
spot was collected on filter paper for gas chromatography-
mass spectrometry (GC-MS) analysis.
2.4. Gas Chromatography-Mass Spectrometry Analysis and
Calculations. Extraction of glucose from blood spots and
GC-MS analysis of extracted glucose were performed accord-
ing to van Dijk et al. [18]. Hepatic glucose production and
metabolic clearance rate were calculated fromGC-MS results
using mass isotopomer distribution analysis as previously
described [18].
2.5. Blood and Tissue Collection. The mice were fasted for 6
hours before being sacrificed. Tissues were rapidly removed,
snap-frozen in liquid nitrogen, and stored at −80∘C until
further analysis. For histology, tissues were frozen or fixed
in paraformaldehyde and embedded in paraffin. Blood was
collected by a heart puncture and separated by centrifugation
(3000 g, 10min, 4∘C). Plasma was decanted and frozen at
−20∘C.
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2.6. Lipid Analysis. For hepatic triglyceride and cholesterol
measurements, lipids were extracted from frozen livers
according to the method of Bligh and Dyer [19]. Hep-
atic and plasma triglyceride and cholesterol levels were
measured using commercially available kits from Roche
(Mannheim, Germany). Hepatic free cholesterol levels were
determined using a commercially available kit from DiaSys
(Holzheim, Germany). For diacylglycerol (DAG) determina-
tion, lipids were extracted from frozen-crushed livers with
MeOH :CHCl
3
(1 : 2) and separated by thin-layer chromatog-
raphy. Lipids were visualized with CuSO
4
and quantified by
comparing the density to a standard amount of DAG.
2.7. Immunoblot Analysis. Frozen tissues were homogenized
for Western Blot analysis. Protein concentration was equal-
ized and proteins were separated with SDS-PAGE and trans-
ferred to polyvinylidene difluoride membranes (GE Health-
care Life Sciences, Diegem, Belgium). Membranes were
incubated overnight at 4∘C with an antibody against pAKT
(Ser473, Cell Signaling Technology, Leiden, Netherlands)
or AKT (Cell Signaling Technology) in 5% bovine serum
albumin.The following day, membranes were incubated with
a secondary antibody containing horse-radish peroxidase
(Goat-anti-rabbit: Bio-Rad, Veenendaal, Netherlands). To
visualize the immune complex, membranes were treated with
enhanced chemiluminescence reaction reagent and a picture
was taken using Gel Doc XR+ Imaging system (Bio-Rad).
Protein bandswere analyzed using Image Lab 3.0.1 (Bio-Rad).
2.8. Gene Expression. To isolate RNA, liver biopsies were
homogenized in Qiazol reagent and RNA was isolated
according to the manufacturer’s procedure (Qiagen, Venlo,
Netherlands). Adipose tissue RNA was isolated using a
commercially available kit (Qiagen). From liver and adipose
tissue RNA, cDNAwas synthesized for RT-PCR using a com-
mercially available kit (Bio-Rad). RT-PCR was performed
using Sybr Green Supermix (Bio-Rad). The following primer
sequences were used for RT-PCR: Tnfa, forward CATCTT-
CTCAAAATTCGAGTGACAA, reverse TGGGAGTAG-
ACAAGGTACAACCC; Mcp1, forward GCTGGAGAG-
CTACAAGAGGATCA, reverse ACAGACCTCTCTCTT-
GAGCTTGGT; Cd68, forward TGACCTGCTCTCTCT-
AAGGCTACA, reverseTCACGGTTGCAAGAGAAACAT-
G; Cd11b, forward TCAGAGAATGTCCTCAGCAG, reverse
TGAGACAAACTCCTTCATCTTC; Ppia forward TTC-
CTCCTTTCACAGAATTATTCCA, reverse CCGCCA-
GTGCCATTATGG.
2.9. Histological Analysis. Paraffin-embedded adipose tis-
sue biopsies were sectioned at 4𝜇m and stained with
hematoxylin-eosin. Frozen liver sections of 5𝜇m were used
to stain for the macrophage marker CD68 (FA11, Abcam,
Cambridge, UK).
2.10. Statistical Analysis. 2-way ANOVA followed by Bonfer-
roni posttests to correct for multiple testing was performed
using Graph-Pad Prism 5.0 (San Diego, USA) to determine
the differences between groups. 1-way ANOVA (Kruskal-
Wallis) was used followed byDunnsmultiple comparison test
was used to determine the differences in phosphorylation
of AKT between the groups. To ensure that the assumption
of homogeneity of variances was met, this was tested before
performing an ANOVA. 𝑃 values < 0.05 were considered
significant. Values are expressed as mean ± SEM and group
sizes are indicated in the figure legends.
3. Results
3.1. Elevated Plasma Levels of Cholesterol and Triglycerides in
Ldlr−/− Mice Fed an HF and HFC Diet. Since dyslipidemia
is an independent predictor of insulin resistance, we first
assessed plasma lipid levels of WT and Ldlr−/− mice fed a
chow, HF, or HFC diet for 2 weeks. Body weight (Figure 1(a))
did not differ between both genotypes; however, liver weight
(Figure 1(b)) was slightly increased in both WT and Ldlr−/−
mice fed anHFC-diet compared to chow-fedWT and Ldlr−/−
mice (HFC versus chow, 𝑃 < 0.05; HFCWT versus HFC KO,
ns). Plasma triglyceride (Figure 1(c)) and cholesterol levels
(Figure 1(d)) were significantly elevated in Ldlr−/− mice fed
an HF- and HFC-diet compared to HF- and HFC-fed WT
mice andLdlr−/−mice fed a chow-diet (Figures 1(c) and 1(d)).
Nevertheless, plasma triglyceride levels were significantly
lower in HFC-fed Ldlr−/− mice compared to HF-fed Ldlr−/−
mice (Figure 1(c)). In contrast, plasma cholesterol levels
were significantly higher in HFC-fed Ldlr−/− mice compared
to HF-fed Ldlr−/− mice (Figure 1(d)). No differences were
observed in plasma FFA levels (data not shown). In addition,
glucose levels were significantly elevated in Ldlr−/− mice
fed an HF-diet compared to HF-fed WT mice (Figure 1(e))
and did not differ between chow- or HFC-fed Ldlr−/− mice
(Figure 1(e)). However, insulin levels were significantly
elevated in Ldlr−/− mice fed an HF and HFC diet compared
to chow-fed Ldlr−/− mice (Figure 1(f)) but were not further
increased by cholesterol addition to the HF diet (Figure 1(f)).
In line with this, the HOMA-IR was significantly elevated
in Ldlr−/− mice fed an HF and HFC diet compared to
both HF- and HFC-fed WT mice and chow-fed Ldlr−/−
mice (Figure 1(g)), confirming the reported predisposition
towards insulin resistance in dyslipidemic Ldlr−/− mice [12].
HOMA-IR levels did not differ between HF- and HFC-fed
Ldlr−/− mice (Figure 1(g)).
3.2. Increased Hepatic Inflammation in Ldlr−/− Mice Fed an
HFC Diet. To validate the degree of hepatic inflammation
in WT and Ldlr−/− mice fed a chow, HF, and HFC diet,
we performed CD68 immunostaining and measured the
expression of the proinflammatory genes Cd68, Cd11b, Tnfa,
andMcp in livers ofWT and Ldlr−/−mice fed a chow, HF, and
HFC diet. As expected, Ldlr−/− mice fed an HFC diet showed
an increased staining of CD68 in the liver (Figure 2(a)),
indicating an increased number of macrophages in their
livers. Being consistent with the histological analysis of the
liver, Ldlr−/− mice on an HFC diet showed marked levels of
hepatic inflammation compared to HFC-fed WT mice. We
observed a 5-fold and a 2-fold increase in the mRNA levels
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Figure 1: Circulating levels of lipids, glucose, and insulin in Ldlr−/− mice fed a chow, HF, or HFC diet for 2 weeks. Body weight (a) and liver
weight (b) ofWT and Ldlr−/− mice fed a chow, high-fat (HF), or high-fat cholesterol (HFC) diet were determined at time of sacrifice (𝑛 = 12).
Plasma triglyceride (c), cholesterol (d), glucose (e), and insulin (f) levels were measured in blood obtained following a 6-hour fast (𝑛 = 5-6).
(g) The homeostasis model assessment of insulin resistance (HOMA-IR) was calculated from fasted insulin and glucose levels (𝑛 = 6). Data
are expressed as means ± SEM for WTmice (white bars) and Ldlr−/− mice (black bars). ∗𝑃 < 0.05WT versus KO; #𝑃 < 0.05HF, HFC versus
chow; $𝑃 < 0.05HF versus HFC.
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Figure 2: Hepatic inflammation in Ldlr−/− mice fed an HFC diet. (a) Representative pictures of frozen liver sections stained with CD68 were
taken fromWT and Ldlr−/− mice fed a chow, high-fat (HF), or high-fat cholesterol (HFC) diet (𝑛 = 5-6). RNA was isolated from liver tissue
and the expression of the proinflammatory genes Cd68 (b), Cd11b (c), Tnfa (d), andMcp1 (e) was determined by real-time PCR and expressed
as fold induction (𝑛 = 5). Data are expressed as means ± SEM for WTmice (white bars) and Ldlr−/− mice (black bars). ∗𝑃 < 0.05WT versus
KO; #𝑃 < 0.05HF, HFC versus chow; $𝑃 < 0.05, HF versus HFC.
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of the macrophage markers Cd68 and Cd11b, respectively
(Figures 2(b) and 2(c)), compared to HFC-fed WT mice. In
addition, a 5-fold increase in the expression of the cytokine
Tnfa (Figure 2(d)) and a 10-fold increase in the expression of
the chemokineMcp1 (Figure 2(e)) were observed in HFC-fed
Ldlr−/− mice compared to HFC-fed WT mice. Furthermore,
increased Cd68 expression was also observed in Ldlr−/− mice
following 2 weeks of HF feeding compared to HF-fed WT
mice (Figure 2(b); 𝑃 < 0.05). However, this HF-diet induced
increase inCd68 expressionwas significantly lower compared
to Ldlr−/− mice fed an HFC-diet (Figure 2(b)). Moreover, HF
feeding did not increase the expression levels of Cd11b, Tnfa,
orMcp1 in the livers of Ldlr−/−mice whereasHFC feeding did
(Figures 2(c)–2(e); Ldlr−/− HF versus Ldlr−/− HFC, 𝑃 < 0.05
for all genes).
3.3. Absence of Adipose Tissue Inflammation in Ldlr−/− Mice
Fed an HFC Diet. Despite marked inflammation in the livers
of Ldlr−/− mice fed an HFC diet, hematoxylin and eosin
staining of white adipose tissue sections did not show signs
of inflammation (Figure 3(a)). In addition, no significant
changes in the gene expression of the inflammatory markers
Cd68, Cd11b, Tnfa, and Mcp were found in white adipose
tissue (Figures 3(b)–3(e)), confirming the absence of adipose
tissue inflammation in Ldlr−/−mice fed any of the given diets.
3.4. Hepatic Insulin Resistance in Dyslipidemic Ldlr−/− Mice Is
Unrelated to Hepatic Inflammation. To investigate the degree
of systemic insulin resistance in dyslipidemic Ldlr−/− mice
with or without hepatic inflammation, we performed an
OGTT and an ITT in Ldlr−/− mice fed a chow, HF, and
HFC diet. The OGTT (Figure 4(a)) and ITT (Figure 4(b))
did not detect differences between the groups, suggesting
that 2 weeks of HF and HFC feeding did not induce notable
changes in glucose and insulin tolerance between the mice.
We next performed a hyperinsulinemic-euglycemic clamp
(HIEC) to distinguish between hepatic and peripheral insulin
resistance. The glucose infusion rate (GIR; Figure 4(c)) and
the metabolic clearance rate of glucose (MCR; Figure 4(d))
did not differ between the mice fed a chow, HF, or HFC
diet, confirming the similar glucose curves observed during
the OGTT and the ITT. However, we observed a significant
increase in hepatic glucose production in Ldlr−/− mice fed an
HF diet compared to HF fed WT mice (Figure 4(e)). These
findings indicate that Ldlr−/− mice fed an HF diet suffered
from hepatic insulin resistance, while peripheral insulin
resistance remained unaffected. Hepatic glucose production
was not increased in Ldlr−/− mice fed an HFC-diet compared
to HFC-fed WT mice (Figure 4(e); ns) and was not worse
than Ldlr−/−mice fed anHFCdiet (Figure 4(e); ns). Although
clear hepatic insulin resistance was observed in Ldlr−/−
mice fed an HF-diet, the Ser473 phosphorylation of AKT
(Figures 4(f) and 4(g)) in the liver was not affected following
insulin stimulation. In fact, no difference was observed in the
insulin stimulated AKT response for any of the given diets
(Figure 4(g)).
3.5. Differences inHepatic Lipid Accumulation Cannot Explain
Hepatic Insulin Resistance. Since the accumulation of lipid
species in the liver has been associated with the development
of hepatic insulin resistance [20–22], we measured hepatic
lipid accumulation in WT and Ldlr−/− mice fed a chow, HF,
or HFC diet for 2 weeks. No difference was observed in
hepatic triglyceride accumulation between WT and Ldlr−/−
mice fed either diet; however, compared to chow-fed mice
triglyceride levels were moderately increased in livers of
WT mice (Figure 5(a); WT HFC versus WT chow, 𝑃 <
0.05). As expected, HFC feeding increased total cholesterol
levels in both WT and Ldlr−/− mice compared to chow
and HF-fed mice and did not differ between the genotypes
(Figure 5(b)). Free cholesterol was significantly increased
but only in Ldlr−/− mice fed an HFC diet (Figure 5(c)). In
particular, DAGs have been associated with the development
of hepatic insulin resistance [21]. However, DAG levels were
similar in both genotypes and on all diets (Figure 5(d)). In
summary, these results suggest that differences in hepatic
lipid accumulation cannot account for the hepatic insulin
resistance observed in Ldlr−/− mice.
4. Discussion
This study was designed to determine the effect of hepatic
inflammation on the development of insulin resistance in
Ldlr−/− mice, while excluding body weight gain as a con-
founding factor. Our results show that Ldlr−/− mice develop
hepatic insulin resistance within 2 weeks of HF feeding, while
peripheral insulin resistance remained unaffected. Our data
also show that both systemic insulin resistance and hepatic
insulin resistance are not more advanced in Ldlr−/− mice fed
an HFC diet, even though these mice had increased levels
of hepatic inflammation compared to both chow and HF-
fed Ldlr−/− mice. These results illustrate that hepatic insulin
resistance can develop prior to alterations in body weight
gain. Moreover, our findings suggest that hepatic inflamma-
tion induced by dietary cholesterol is not associated with the
onset of hepatic insulin resistance during this time frame
and indicate that cholesterol-induced hepatic inflammation
cannot explain the predisposition towards insulin resistance
in these Ldlr−/− mice.
Our results also suggest that dyslipidemia is not causal to
the development of hepatic insulin resistance as the degree
of dyslipidemia was identical amongst the HF- and HFC-fed
Ldlr−/− mice (Figures 1(b) and 1(c)) whereas hepatic insulin
resistance was only observed in the HF-fed Ldlr−/− mice
(Figure 4(e)). This argues against a causal relationship in the
well-established metabolic link between hyperglycemia and
dyslipidemia. Indeed, dyslipidemia, at the clinical level, is
associated with elevated plasma glucose levels and insulin
resistance. Furthermore, patients diagnosed with familial
combined hyperlipidemia have an increased incidence of
insulin resistance and T2D [23–27]. Moreover, dyslipidemia
is an independent predictor for the development of insulin
resistance and T2D later in life. Nevertheless, there is a
complex genetic regulation and metabolic interplay between
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Figure 3: Absence of adipose tissue inflammation in Ldlr−/−mice fed a chow, HF, or HFC diet for 2 weeks. Representative pictures of paraffin-
embedded white adipose tissue sections stained with hematoxylin-eosin (a) were taken from WT and Ldlr−/− mice fed a chow, HF, or HFC
diet (𝑛 = 5-6). RNA was isolated from white adipose tissue and the expression of the proinflammatory genes Cd68 (b), Cd11b (c), Tnfa (d),
and Mcp1 (e) was determined by real-time PCR and expressed as fold induction (𝑛 = 11-12). Data are expressed as means ± SEM for WT
mice (white bars) and Ldlr−/− mice (black bars).
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Figure 4: Hepatic inflammation does not induce hepatic insulin resistance in lean Ldlr−/− mice. To assess systemic insulin resistance, we
performed an oral glucose tolerance test (a) and an insulin tolerance test (b) in WT and Ldlr−/− mice fed a chow, high-fat (HF), or high-fat
cholesterol (HFC) diet (𝑛 = 5-6). To distinguish between hepatic and peripheral insulin resistance, a hyperinsulinemic-euglycemic clamp
was performed during which glucose infusion rate (GIR) (c), metabolic clearance rate (MCR) (d), and hepatic glucose production (HGP) (e)
were determined (𝑛 = 5–7). (f) Phosphorylation status of AKT in liver tissues obtained from WT and Ldlr−/− mice fed a chow, HF, or HFC
diet sacrificed 15min after saline (𝑛 = 5) or insulin injection (𝑛 = 7) and determined by Western Blot analysis. Data are expressed as means
± SEM for WT mice (white bars) and Ldlr−/− mice (black bars). ∗𝑃 < 0.05WT versus KO; #𝑃 < 0.05 HF, HFC versus chow; $𝑃 < 0.05 HF
versus HFC.
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Figure 5: Differences in hepatic lipid accumulation cannot explain hepatic insulin resistance. To assess hepatic lipid accumulation, we
measured levels of triglycerides (a) cholesterol (b), free cholesterol (c), and 1,2 DAG (d) in liver tissue of WT and Ldlr−/− mice fed a chow,
high-fat (HF), or high-fat cholesterol (HFC) diet. Data are expressed as means ± SEM forWTmice (white bars) and Ldlr−/− mice (black bars)
(𝑛 = 5). ∗𝑃 < 0.05 versus wild type. ∗𝑃 < 0.05, WT versus KO; #𝑃 < 0.05HF, HFC versus chow; $𝑃 < 0.05, HF versus HFC.
lipid and glucose metabolism, as we have recently observed
that the genetic predisposition to dyslipidemia is related to
lower levels of fasting plasma glucose, HbA1c, and HOMA-
IR [28]. Out of the 15 loci that are associated with both
lipids and glucose-related traits independently, 8 (CETP,
MLXIPL, PLTP, GCKR, APOB, APOE-C1-C2, CYP7A1, and
TIMD4) did exert an opposite allelic effect on dyslipidemia
and glucose traits [28].
In contrast to several publications that indicate that
hepatic inflammation can cause insulin resistance [29, 30], we
found that hepatic inflammation did not advance the devel-
opment of peripheral insulin resistance in female Ldlr−/−
mice. This confirms our previous findings in male Ldlr−/−
mice fed a 2-week HFC diet [4] suggesting that similar
phenomena exist between male and female Ldlr−/− mice in
terms of systemic insulin resistance. Whether hepatic insulin
resistance is also unrelated to hepatic inflammation in male
Ldlr−/− mice remains to be investigated. An explanation for
the lack of an effect of hepatic inflammation on insulin
resistancemay be found in the cell type driving inflammation.
Cai et al. described how inflammation was induced by
hepatocyte activation of IKK, and this resulted in hepatic and
systemic insulin resistance [30]. Though being not assessed
in this paper, previous studies have shown that Kupffer
cells become foamy in Ldlr−/− mice within 7 days of HFC
feeding and may be responsible for the initiation of hepatic
inflammation in this model [14, 15]. Kupffer cells are thought
to contribute to insulin resistance by the production of
proinflammatory cytokines that inhibit insulin signaling in
hepatocytes [31]. Nevertheless, there is conflicting evidence
for the role of Kupffer cells in hepatic insulin resistance.
Some papers report an amelioration of insulin resistance with
a depletion of Kupffer cells [32, 33], whereas others show
deterioration in insulin resistance [34]. Moreover, depleting
Kupffer cells after the induction of insulin resistance has no
therapeutic effect on metabolic changes [5]. Therefore, the
cell type driving the hepatic inflammation may be important
in determining the effect on insulin resistance. Hepatocyte-
derived inflammation may be more important than Kupffer
cell activation in the development of insulin resistance,
highlighting the need for more studies focusing on cell type-
specific induction of inflammation.
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The lack of an effect of hepatic inflammation on insulin
resistance may also reflect a time-dependent effect. A recent
paper reported that inflammation was only involved in diet-
induced insulin resistance once obesity had been established
and not during the onset of obesity [35]. When obesity
is established, a crosstalk between adipose tissue and liver
may start to play a role. Hence, an HFC diet induces
insulin resistance in Ldlr−/− mice only after 24 weeks of
HFC feeding, which is presumably caused by adipose tissue
inflammation [36]. In another study, the proinflammatory
cytokines secreted from adipose tissue were shown to be
able to induce insulin resistance in hepatocytes [37]. Hepatic
inflammation has been shown to develop within 4 days
of HFC feeding in female Ldlr−/− mice [14]. Thus, in our
experimental model, hepatic inflammation was present for
approximately 1.5 weeks, without increased body weight
gain or adipose tissue inflammation (Figures 2(b) and 3(c))
being present. This may not be long enough for hepatic
inflammation to inhibit insulin signaling in the liver.Our data
indicate that cholesterol-induced hepatic inflammation, in
the absence of adipose tissue inflammation, is not enough to
induce insulin resistance in hepatocytes. Within this 2-week
time framehepatic insulin resistancemay be primarily caused
by factors other than hepatic inflammation and dyslipidemia.
A few limitations of our studymust be taken into account.
While there is no doubt about the hepatic insulin resistance
observed in Ldlr−/− fed an HF diet during the HIEC, we were
not able to confirm these results by measuring phosphoryla-
tion of AKT in the livers of insulin injected mice. This may
be explained by the many pathways and molecules that are
involved in insulin signaling [38]. Interference with insulin
signaling may take place at a different part of the insulin
signaling cascade than at the level of AKT. In addition, while
we excluded differences in hepatic lipid content that may
affect hepatic insulin resistance, we cannot rule out that other
changes that could occur in Ldlr−/− mice might contribute to
their hepatic insulin resistance. Lack of the Ldlr may lead to
differences in intracellular signaling cascades that could affect
insulin signaling. However, in chow-fed Ldlr−/− mice, we
observed no changes in either hepatic or peripheral insulin
resistance, indicating that the effects on hepatic insulin
resistance are not intrinsic to the Ldlr deficiency but are
related to the HF-diet intervention in these mice. Moreover,
the fact that HFC feeding induced more severe hepatic
inflammation and less insulin resistance than did HF feeding
does not necessarily indicate that inflammation can be denied
as being the cause of insulin resistance in Ldlr−/− mice. The
results may thus suggest that cholesterol addition to the
HF diet alleviates hepatic insulin resistance in Ldlr−/− mice.
As a result, we cannot exclude that deterioration of insulin
resistance induced by the hepatic inflammation may have
been overcome by the insulin sensitizing effect of cholesterol.
Nevertheless, we cannot explain why cholesterol addition
to the HF diet confers protection against the development
of hepatic insulin resistance in Ldlr−/− mice. This may be
related to Kupffer cell activation triggered by the cholesterol
in the diet [4], since factors derived from Kupffer cells have
been shown to work in a transacting manner to maintain
hepatic lipid homeostasis [32]. Further studies are required
to understand this effect.
5. Conclusions
In conclusion, our data show that neither cholesterol-induced
hepatic inflammation nor dyslipidemia is causally related
to the development of hepatic insulin resistance in Ldlr−/−
mice. As chronic inflammation is considered a causal risk
factor predisposing to insulin resistance, our data suggests
that inflammation when confined to the liver may not be
causal to metabolic dysfunction.
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